Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The company went IPO on 2021-02-17. The firm is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.

Industry: Pharmaceutical Preparations Peers: Capricor Therapeutics Inc Celcuity Inc Icosavax, Inc. IPI Legacy Liquidation Co Jounce Therapeutics, Inc. Larimar Therapeutics Inc Matinas BioPharma Holdings Inc Precision BioSciences Inc Werewolf Therapeutics Inc